Palvella Therapeutics, Inc.
$129.33
▲
2.56%
2026-04-21 09:00:00
palvellatx.com
NCM: PVLA
Explore Palvella Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.85 B
Current Price
$129.33
52W High / Low
$151.18 / $20.2
Stock P/E
—
Book Value
$2.26
Dividend Yield
—
ROCE
-80.06%
ROE
-92.1%
Face Value
—
EPS
$-3.71
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
29
Beta
—
Debt / Equity
65.73
Current Ratio
5.2
Quick Ratio
5.2
Forward P/E
-19.32
Price / Sales
—
Enterprise Value
$1.78 B
EV / EBITDA
—
EV / Revenue
—
Rating
Strong Buy
Target Price
$230.07
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Moderna, Inc. | $55.11 | — | $21.94 B | — | -29.7% | -28.87% | $59.55 / $22.28 | $21.95 |
| 2. | ProQR Therapeutics N.V. | $1.84 | — | $206.51 M | — | -54.09% | -61.17% | $3.1 / $1.1 | $0.54 |
| 3. | Abeona Therapeutics Inc. | $5.48 | 4.39 | $312.63 M | — | -47.08% | 70.05% | $7.54 / $4 | $2.89 |
| 4. | Arcturus Therapeutics Holdings Inc. | $8.9 | — | $251.54 M | — | -32.48% | -28.92% | $24.17 / $5.85 | $7.53 |
| 5. | Century Therapeutics, Inc. | $2.34 | — | $467.28 M | — | -5.16% | -5.98% | $3.04 / $0.43 | $1.82 |
| 6. | BiomX Inc. | $1.46 | — | $9.55 M | — | -101.67% | -3.17% | $14.71 / $1.5 | $-12.5 |
| 7. | Jasper Therapeutics, Inc. | $1.06 | — | $28.56 M | — | -371.51% | -2.3% | $7.19 / $0.62 | $0.15 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -11.3 M | -10.18 M | -9.25 M | -7.87 M | -4.37 M | — |
| Net Profit | -12.71 M | -11.35 M | -9.47 M | -8.19 M | -3.95 M | — |
| EPS in Rs | -0.89 | -0.79 | -0.66 | -0.57 | -0.28 | -0.62 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -38.6 M | -14.1 M | -11.87 M | -18.04 M |
| Net Profit | -41.72 M | -17.43 M | 18.69 M | -27.55 M |
| EPS in Rs | -2.91 | -1.22 | 1.31 | -1.92 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 59.56 M | 88.23 M | 7.55 M | 16.52 M |
| Total Liabilities | 31.58 M | 25.63 M | 11.43 M | 39.7 M |
| Equity | 27.98 M | 62.61 M | -3.88 M | -23.17 M |
| Current Assets | 58.99 M | 88.23 M | 7.55 M | 16.52 M |
| Current Liabilities | 11.34 M | 12.04 M | 2.36 M | 5.78 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -25.01 M | -10.84 M | -13.7 M | -14.84 M |
| Investing CF | — | — | — | — |
| Financing CF | -0.66 M | 87.09 M | 5 M | 9.57 M |
| Free CF | -25.01 M | -10.84 M | -13.7 M | -14.84 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -139.27% | -193.27% | 167.84% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-04-23 | 1:0.0125 |